Daniel O'Day, AP Images

Com­mer­cial strat­e­gy for Gilead­'s Covid-19 drug-to-be remde­sivir re­mains opaque, as chief O'­Day em­pha­sizes re­spon­si­bil­i­ty

In his open­ing re­marks on Thurs­day, Gilead chief Daniel O’Day did us all a fa­vor, trun­cat­ing his com­men­tary on the quar­ter gone by to set aside more time to dis­cuss in de­tail remde­sivir: the com­pound at the heart of ef­forts to com­bat Covid-19.

But the big ques­tion re­mained — does Gilead plan to gen­er­ate a re­turn on its in­vest­ment in the drug? O’Day did not an­swer that ques­tion di­rect­ly, in­stead, he em­pha­sized the need for re­spon­si­bil­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.